Effective price per mg uses an active dated override first, then the row-level historical discount, then the vendor default from the same Git revision. Aggregate chart points include exact-comparability offers only. Missing observations remain gaps; the series does not interpolate across unavailable offers or absent snapshots.

Price watch · beta

Let the market come to you.

Watch the best market price or one vendor. Get one email when Thymosin Alpha-1 crosses your target, drops, or sets a new tracked low—without daily noise.

Price scope Alert me Target per mg

$/mg

Confirmed Weekly Peptide Intel email

Requires a confirmed Weekly Peptide Intel address, then a separate alert confirmation. Already watching? Manage price alerts. Public prices can change; confirm the final cart total.

Public product evidence 130 certificate records for Thymosin Alpha-1 products, from 60 vendors 62 reference a report on the testing laboratory's own system · 57 have a laboratory lookup that answered when last checked · 114 match a vendor product page at the same address

Status

Investigational

This compound has a genuine development or study trail, but it is not an approved routine drug.

Research area

Immune / inflammation research

This profile is grouped by its dominant research area, not by vendor shelf placement.

Body systems

Immune

Where the compound acts, as a browse axis. It is an editorial grouping for discovery, not a claim about labeled indications.

Aliases

Tα1, Thymalfasin

Signal depth

Medium

No FDA label signal · 83 trials · 1157 PubMed results

Promising

Research evidence

Thymosin Alpha-1 has name-matched human trials with published or reported controlled evidence, but is not FDA-approved. The research is real and ongoing — treat findings as developing rather than settled.

Thymosin Alpha-1 has 26 name-matched clinical trials (highest phase: Phase 4) and 1157 PubMed-indexed publications and is not FDA-approved. 2 trials have posted results.

Human data

Phase 3

Trial quality

Large RCT

Outcomes

Clinical outcomes

Replication

Meta-analysis

Literature

High-impact

PHASE4 · Randomized Thymosin Alpha 1 in the Prevention of Pancreatic Infection Following Acute Necrotizing Pancreatitis PHASE4 · Randomized Thymalfasin Adjuvant Therapy in Hepatitis B Virus (HBV)-Related Hepatocellular Carcinoma (HCC) After Curative Resection PHASE4 · Randomized Efficacy and Safety of Combination Therapy of Thymalfasin and Entecavir in HBeAg-positive ETV-experienced Patients The Journal of Immunology · 235 citations Ta1, a novel 105 KD human T cell activation antigen defined by a monoclonal antibody. Proceedings of the National Academy of Sciences · 182 citations Prothymosin alpha: isolation and properties of the major immunoreactive form of thymosin alpha 1 in rat thymus. Applied Physics Letters · 156 citations Structural distortion and ferroelectric properties of SrBi2(Ta1−xNbx)2O9

Evidence history

Re-checked nightly against the registries — tracked since 2026-07-09. No band changes yet.

Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-10-18 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →

What thymosin alpha-1 is

Thymosin alpha-1 is an immune-oriented peptide associated with T-cell and immunomodulatory signaling. It stands apart from many retail peptide names because it has a longer clinical-research history than a typical gray-market recovery compound.

Why it matters

It gives the peptide library a credible anchor for the immune category and helps show that not every non-FDA-approved peptide sits in the same bucket of evidence or seriousness.

Regulatory context

Thymosin alpha-1 is not an FDA-approved peptide drug indication in the United States, but it has been investigated in more formal clinical contexts than many research-market peptides.

Practical reading note

This is exactly the kind of profile where “not FDA approved” should not be confused with “fringe.” The important distinction is between investigational clinical use and generic research-market marketing.